Is BPC-157 FDA approved?
No — BPC-157 is not approved by the FDA, Health Canada, the EMA, the TGA, or any other major regulator for therapeutic use in humans or animals. The compound is supplied as a research-grade reagent for laboratory and bench-research applications only. The published human-cohort literature consists of small pilot studies and preclinical-model work; no large-scale human clinical trials have completed.
What the research literature says
BPC-157’s regulatory status reflects its position in the research-supply tier rather than the pharmaceutical-development tier. The compound has been studied in preclinical research since the early 1990s by the Sikiric-Seiwerth research group in Croatia, with cross-laboratory replication of core findings published by independent investigators (PMID 30915550). The accumulated preclinical literature spans wound-healing models (PMID 34267654), gastrointestinal-protection research (PMID 38980576), pleiotropic activity reviews (PMID 38675421), and musculoskeletal repair work.
The published human-cohort literature is comparatively limited. A 2024 pilot trial in interstitial cystitis (PMID 39325560) is among the small set of published human-subject studies. No phase 2 or phase 3 clinical-trial programs comparable to the SUSTAIN, STEP, or SURPASS programs for the incretin-class compounds have been published or registered for BPC-157.
The compound is supplied for laboratory-research use only. Sale is limited to research applications; human and veterinary therapeutic use are explicitly excluded from the research-supply framework.
Why this matters in research context
The regulatory-status question matters for any researcher considering BPC-157 work because it shapes the experimental-context options. Preclinical animal-model research operates within the existing IACUC and institutional-protocol frameworks for research-use compounds. Human-subjects research with BPC-157 would require IRB approval under research-use-only framing and is operationally distinct from the FDA-approved-drug research pathway.
Related compounds
- BPC-157 10mg — the compound covered by this answer
- BPC-157 (glossary entry) — regulatory status, mechanism, history
Related research questions
- Are research peptides legal in Canada?
- Are research peptides legal in the US?
- How does BPC-157 work?
References
- Cerovecki T et al. Gastric pentadecapeptide body protection compound BPC 157 and musculoskeletal soft tissue healing. Cell Tissue Res 2019. [PMID 30915550]
- Gwyer D et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol 2021;12:627533. [PMID 34267654]
- Sikiric P et al. New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. Inflammopharmacology 2024;32(5):3119-3161. [PMID 38980576]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. BPC-157 is sold strictly as a research-grade reagent for laboratory and bench research applications.